Work

KarMMa-4: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy in high-risk newly diagnosed multiple myeloma.

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.15_suppl.tps8053

Authors: Saad Z. Usmani, Jesus G. Berdeja, Anna Truppel-Hartmann, Yizhou Fei, Honeylet Wortman-Vayn, Suresh Shelat, Steven Novick, Nina Shah

Institutions: Levine Cancer Institute, Sarah Cannon, Tennessee Oncology, Bluebird Bio (United States), Bristol-Myers Squibb (United States), University of California, San Francisco

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3167575367

Cites:

Cited by: 19

Related to: 10